Athena - Heart [310]

: Periodic testing is recommended due to reported cases of liver injury.

: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL). ATHENA HEART [310]

The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death. : Periodic testing is recommended due to reported

Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted. Patients with paroxysmal or persistent AF or AFL

Stop other Class I or III antiarrhythmics (e.g., amiodarone, sotalol) before starting Multaq. Avoid strong (e.g., ketoconazole).

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial